Dentsply Sirona announced on September 8, 2025, that it has completed its evaluation of strategic alternatives for the Wellspect Healthcare business, a process initiated in February 2025. Following an extensive review, the company determined that retaining Wellspect as a subsidiary within its portfolio will create more value for Dentsply Sirona stockholders than other available alternatives.
Wellspect is recognized as a category leader in the global continence care market, boasting a high-quality product pipeline, strong cash flow generation, and significant untapped market potential. The business delivered mid-single-digit organic sales growth in 2024, operating within an estimated $2 billion addressable market.
CEO Dan Scavilla stated that recent investments in Wellspect are generating results, and the business is expected to play an important role in the company's strategy to deliver durable, profitable growth across the entire Dentsply Sirona portfolio. This decision provides clarity on the future of the Wellspect segment within the company's overall strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.